This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Merck's Keytruda Gets 2nd Label Expansion Approval in June
by Zacks Equity Research
Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.
Big Drugmakers That May Tread the M&A Path After Pfizer
by Kinjel Shah
There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
Roche's Rozlytrek Gets Approval in Japan for Solid Tumors
by Zacks Equity Research
Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
Top Analyst Reports for Broadcom, Amgen & NVIDIA
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Broadcom (AVGO), Amgen (AMGN) and NVIDIA (NVDA).
Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti
by Zacks Equity Research
FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.
Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
by Zacks Equity Research
Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.
Ligand Inks Oncology Drug Discovery Deal With PhoreMost
by Zacks Equity Research
Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.
Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock
by Zacks Equity Research
Here are five reasons why investors may consider betting on Merck (MRK) stock
Roche's Rituxan Gets Priority Review for Blood Disorder
by Zacks Equity Research
Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $175.60, moving +0.56% from the previous trading session.
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
by Zacks Equity Research
Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.
Roche Receives FTC Request for Further Data on Spark Buyout
by Zacks Equity Research
Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $174.45, marking a -0.06% move from the previous day.
Lilly's Emgality Gets FDA Approval for Cluster Headache
by Zacks Equity Research
Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.
Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
by Kinjel Shah
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Pfizer to Launch Several Drugs Despite Generic Headwinds
by Zacks Equity Research
Pfizer (PFE) looks well positioned to launch several breakthrough innovative medicines in the next five years amid loss of exclusivity headwinds.
Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity
by Zacks Equity Research
At ASCO, Amgen (AMGN) presented encouraging initial data set for AMG 510, its novel investigational KRAS inhibitor for solid tumor.
Company News For Jun 4, 2019
by Zacks Equity Research
Companies In The News Are: EE,CY,AMGN,MRK
Why Cancer-Fighting Stocks & ETFs Are Soaring
by Neena Mishra
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $166.70 in the latest trading session, marking a -1.38% move from the prior day.
Amgen (AMGN) Down 4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amarin Rises on Priority Review for Vascepa Label Expansion
by Zacks Equity Research
Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.
Merck (MRK) Up This Year So Far: Will the Momentum Continue?
by Kinjel Shah
Merck's shares are up 6.2% this year so far on strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.